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Abstract 
Pseudomyxoma peritonei (PMP) is a rare tumor syndrome that can be diagnosed in 
association with mucinous ovarian tumors of low malignant potential. Surgical debulking 
is the primary treatment modality as chemotherapy has generally proven ineffective in 
this slowly progressive tumor. When patients with PMP are not surgical candidates, there 
is no effective treatment, and patients will die of progressive disease. We report two 
patients with PMP with associated mucinous ovarian tumor of low malignant potential 
treated with Bevacizumab therapy. Both patients demonstrated disease response to 
single agent Bevacizumab therapy. One patient had a prolonged response while on 
therapy, remained stable for 6 months when treatment was held, and then after 
progressing responded to a second course of therapy. We discuss here (1) the clinical 
features which may predict a better response to Bevacizumab therapy, and (2) evidence 
for the use of chemotherapy for inoperable PMP. These cases suggest that Bevacizumab 
may represent a rare effective therapy for patients with inoperable PMP with ovarian 
involvement and should be considered for clinical trials in this patient population.  
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Introduction 
Pseudomyxoma peritonei (PMP) is a rare syndrome characterized by loculated 
gelatinous ascites and peritoneal dissemination of tumor implants [1]. Patients present 
with symptoms of increasing abdominal girth, bloating, nausea and occasionally intestinal 
obstruction. PMP is reported to originate primarily from gastrointestinal tumors, 
however, PMP has been associated in patients with mucinous ovarian tumors of low 
malignant potential (LMP) and in association with mature cystic teratomas [2]. In 
addition, because many patients with PMP of intestinal origin can present with ovarian 
masses and peritoneal disease consistent with ovarian malignancy, many of these patients 
are treated by gynecologic oncologists. 
The diagnosis of PMP associated with ovarian invasion versus primary ovarian tumor 
remains difficult as appendiceal tumors and borderline mucinous ovarian tumors have 
very similar histological appearances. Histopathologically, PMP is sub-classified into 
high-grade peritoneal mucinous carcinomatosis (PMCA) [3] or low-grade disseminated 
peritoneal adenomucinosis (DPAM). PMCA demonstrates aggressive growth patterns, 
invasion and a poorer prognosis. Histologically DPAM can be indistinguishable from 
intestinal type mucinous ovarian LMP tumors. Similar to ovarian LMP tumors, DPAM 
PMP tends to be slow growing with a more indolent course. 
Regardless of the origin of PMP, traditional treatment for PMP has consisted of 
aggressive, serial surgical debulking and/or stripping procedures [4]. In an attempt to 
improve results, several groups have studied the addition of hyperthermic intraperitoneal 
chemotherapy (HIPEC) administered at the time of debulking. Limited trials and case 
series have suggested improved survival with HIPEC [5]. In addition with increased 
experience, morbidity has been reduced. However, morbidity can still be significant, 
many patients are not candidates for surgery or HIPEC, and HIPEC is not available at 
many centers. Even after aggressive surgery and HIPEC, many patients can progress 
either as a result of technical complications or disease biology [6]. 
When patients with PMP are not surgical candidates, they ultimately succumb to the 
underlying cancer. The use of traditional chemotherapy has not demonstrated a survival 
advantage over surgery alone [7]. Biologic therapy, therefore, has appeal for the treatment 
of PMP. Bevacizumab (Bevacizumab, Genentech) binds to the vascular endothelial 
growth factor (VEGF) and inhibits angiogenesis. We speculated that Bevacizumab would 
be an effective agent against PMP with significant ovarian invasion because: (1) VEGF 
levels at the time of cytoreductive surgeries for PMP have been inversely correlated with 
survival [8], (2) Bevacizumab has activity in other non-chemoresponsive cancers [9], and 
(3) Bevacizumab has activity in both gastrointestinal tumors and refractory ovarian 
cancer [10, 11]. We describe here two patients with unresectable PMP and ovarian 
mucinous LMP tumors treated with Bevacizumab. 
Case Reports 
Case 1 
A 33-year-old female presented with bloating and constipation. Ultrasound revealed bilateral 
ovarian masses with diffuse carcinomatosis. She underwent a modified radical TAH-BSO and 
omentectomy with optimal debulking. Pathology revealed a stage IIIb mucinous ovarian LMP tumor 
with associated PMP. No gross appendiceal involvement was noted at the time of surgery and an 
appendectomy was not performed. The patient showed signs of disease progression early after surgery  
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and she was treated with multiple chemotherapy regimens including 7 cycles of carboplatinum-
paclitaxel, 3 cycles of topotecan, 5 cycles of liposomal doxorubicin, 32 cycles of gemcitabine, 3 cycles of 
etoposide and 2 cycles of doxorubicin-cyclophosphamide. With each she demonstrated progressive 
disease. 
The patient then transferred care to our center. She underwent an aggressive interval debulking, 
however, she was deemed not to be a candidate for HIPEC. Pathology revealed diffuse peritoneal 
adenomucinosis consistent with PMP. Postoperatively she progressed and continued to have symptoms 
of bloating and early satiety. Her CA19-9 was 523. Bevacizumab was initiated at 10 mg/kg every other 
week. While on Bevacizumab therapy, the patient’s CA19-9 steadily declined, and her symptoms of 
bloating and early satiety dramatically improved. Treatment was complicated by hypertension and 
proteinuria (1.8 g urine protein/24 h) and treatment was temporarily held for two weeks while anti-
hypertensives were initiated. The patient’s blood pressure was controlled with amlodipine and captopril. 
While off therapy there was a modest rise in the CA19-9. With re-initiation of Bevacizumab there was a 
further decline of the CA19-9 to 207. The patient received a total of 11 cycles of Bevacizumab therapy 
over approximately 9 months (fig. 1ai), then once again developed significant proteinuria (>2 g urine 
protein/24 h) requiring discontinuation of therapy. 
The patient was monitored off therapy with stable symptoms and CA19-9 laboratory values for 6 
months. She then developed increasing abdominal pressure and nausea/vomiting. Her CA19-9 was 
significantly elevated to 617. A CT scan demonstrated an increase in ascites and a partial increase in 
solid tumor burden (fig. 1b). The patient’s blood pressure remained well-controlled on medication and 
the patient’s proteinuria had nearly resolved (168 mg urine protein/24 h). Bevacizumab was reinitiated. 
Once again, on therapy the patient experienced a complete resolution of symptoms and the CA19-9 
declined (fig. 1ai). CT scan revealed a reduction in ascites and a stable appearance of solid tumor burden 
(fig. 1b). Currently, the patient has received 9 additional months of Bevacizumab therapy without 
adverse side-effects, though there has been a slight worsening of her proteinuria. 
Case 2 
A 78-year-old female presented with abdominal bloating and was found to have a large pelvic mass. 
She underwent a TAH-BSO, appendectomy, omentectomy and debulking. Pathology revealed a stage 
IIIc ovarian mucinous LMP tumor and associated PMP. Postoperatively, the patient was asymptomatic 
for 30 months but then presented with progressive disease. At that time she underwent a second 
surgery. She had a right colectomy, partial small bowel resection, splenectomy and distal 
pancreatectomy. Despite the aggressive surgery the patient had a suboptimal debulking. She was unable 
to receive HIPEC secondary to intraoperative complications. Within 3 months of surgery she had 
clinically evident disease on exam, and she presented to our institution for transfer of care. 
At that time the patient’s CA19-9 was 202.5, and on exam she had palpable diffuse carcinomatosis of 
her abdomen. She was reluctant to receive chemotherapy and was initiated on Bevacizumab 
monotherapy. The patient’s CA19-9 peaked at 234 after the first cycle of therapy. After successive cycles 
of therapy, the CA19-9 decreased to 180 and the patient reported significant symptom improvement 
(fig. 1aii). After 6 cycles, the patient’s physical exam demonstrated increasing tumor burden and the 
CA19-9 began to increase. Therapy with weekly carboplatinum and biweekly Bevacizumab was started. 
The response was again observed for an additional 4 months at which point the treatment was 
discontinued secondary to worsening symptoms. 
Discussion 
We present here two cases of inoperable, progressive PMP diagnosed in association 
with mucinous ovarian LMP tumors treated with Bevacizumab. Each of these patients 
responded to single agent Bevacizumab therapy. However, the quality and duration of the 
response for each of these patients was rather distinct. Patient 1 responded for over 9 
months until therapy was held secondary to proteinuria, remained stable for 6 months, 
and then responded for an additional 9 months with re-initiation of single agent therapy. 
Patient 2 responded to single agent therapy for approximately 4 months and then 
progressed. She then responded for an additional 4 months to combination therapy with 
Bevacizumab and chemotherapy, before once again progressing.  
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The distinct difference in durability of response may relate to several clinical 
differences which distinguish the two patients. Patient 1 had an optimal interval 
debulking surgery, whereas patient 2 was suboptimally debulked at her interval surgery. 
Patient 1 was relatively young, whereas patient 2 was an octogenarian at the time of 
Bevacizumab therapy. Interestingly, Lee et al. [12] reported age as the only prognostic 
factor in comparing outcomes among groups with ovarian associated PMP, suggesting 
age plays a significant role in disease biology. Surprisingly, patient 1 had progressed 
through several lines of chemotherapy yet demonstrated response within 2 cycles of 
therapy with Bevacizumab (fig. 1). In contrast patient 2 was chemo-naïve at the time of 
Bevacizumab therapy. Thus younger, optimally debulked patients may be excellent 
candidates for a trial of Bevacizumab therapy, regardless of previous chemotherapy 
exposure. 
Therapy with Bevacizumab was generally well-tolerated in both of these patients. 
Patient 1 developed hypertension that was controlled with medication. She also developed 
worsening proteinuria requiring a prolonged suspension of therapy. Her proteinuria 
resolved after 4 months. No evidence of significant hemorrhage, deep-venous thrombosis, 
or gastric perforation was seen. 
The origins of PMP remain somewhat controversial. While the majority of PMP is 
believed to originate from appendiceal/gastrointestinal tumors, rarely it can be associated 
with tumors from other sites. PMP has been reported in association with ovarian tumors, 
including mucinous LMP tumors and cystadenocarcinomas arising from mature cystic 
teratomas [2]. However, recent molecular and immunohistochemical studies suggest that 
many PMP-associated ovarian tumors are actually gastrointestinal tumors with ovarian 
invasion [13]. 
Both of our patients had PMP diagnosed in conjunction with mucinous ovarian LMP 
tumors. Patient 1 had her primary surgery at a community center and did not have an 
appendectomy so may have had appendiceal disease. Interestingly, patient 2 had primary 
surgery, which included appendectomy, at a major academic center. Pathology revealed 
no evidence of appendiceal disease and intra-ovarian disease without surface 
involvement, more consistent with ovarian primary. 
Regardless of the origin, the long-term prognosis for recurrent PMP is poor secondary 
to disease progression [1, 12]. PMP is classically thought to be resistant to systemic 
chemotherapy. There have been case reports of pseudomyxoma response to 
chemotherapy. One patient with a progressive DPAM tumor with neuroendocrine 
features demonstrated response to therapy with intravenous gemcitabine [14]. A second 
report suggested activity of FOLFOX chemotherapy delivered adjuvantly to a patient after 
surgery for an appendiceal pseudomyxoma. The patient was treated with 10 months of 
chemotherapy and remained without evidence of disease progression at 21 months. More 
importantly, the first clinical trial suggesting a potential benefit from chemotherapy in 
this patient population was recently reported. A phase II trial of mitomycin-C and 
capecitabine in 40 patients with non-resectable PMP reported response or stable disease 
in 38% of patients [15]. Two thirds of these patients had DPAM. Of the patients with 
progressive disease, only 14% demonstrated a reduction in disease (3 with decreased 
ascites and 1 with a decrease in tumor burden). Tumor marker responses in these patients 
appeared to correlate with disease response. Interestingly, two thirds of eligible patients 
reported an improvement in their quality of life while on therapy due to a reduction in 
symptoms.  
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While this phase II study is encouraging, further management strategies for PMP are 
clearly necessary; the majority of patients in this study did not receive a clinical benefit. 
Our experience with Bevacizumab suggests a relatively non-toxic therapy with significant 
activity in ovarian PMP worthy of further study. Similar to the patients in the trial with 
mitomycin-C and capecitabine, our patients demonstrated tumor marker response that 
correlated with disease response. Patient 1 demonstrated a clear reduction in her ascites as 
well as tumor. Patient 2 had a clinical and biomarker response to both single agent 
Bevacizumab and Bevacizumab in combination with chemotherapy. This report provides 
an initial rationale for the use of Bevacizumab in clinical trials in PMP. Given the 
improved activity observed with Bevacizumab in combination with chemotherapy in 
other solid tumors and the recent report of an active chemotherapeutic regimen for PMP, 
trials with Bevacizumab as a single agent or in combination with chemotherapy for 
unresectable PMP may be warranted. 
 
 
 
Table 1. Contrasting clinical characteristics of the two reported cases 
  Patient 1  Patient 2 
Age, years  38 (33 at presentation)  82 (78 at presentation) 
Tumor stage  IIIb  IIIc 
Optimal interval debulking  Yes  No 
Prior chemotherapies, n  6  None 
Time from interval debulking surgery  
to therapy 
 
2 months 
 
13 months 
Progression-free survival  >13 months and 
>8 months with retreatment 
5 months 
Side-effects Hypertension,  proteinuria  Neuropathy 
 
 
 
  
Case Rep Oncol 2010;3:1–8 
DOI: 10.1159/000270179 
Published online: January 12, 2009  © 2010 S. Karger AG, Basel 
ISSN 1662–6575 
www.karger.com/cro 
 
 
6
Fig. 1. Disease response to Bevacizumab therapy. a CA19-9 biomarker response to Bevacizumab 
therapy in patient 1 (i) and patient 2 (ii), respectively. Light gray bars indicate administration of single 
agent Bevacizumab. Dark gray bar indicates administration of Bevacizumab and carboplatinum. The 
timing of serial CT scans shown in b are indicated with asterisks. b CT scan of patient 2 with serial 
scans demonstrating disease state after the first course of Bevacizumab therapy (left panels), evidence 
of progression after discontinuation of therapy (middle panels) and stabilization of disease with re-
initiation of therapy (right panels). Boxes indicate representative splenic lesion. The arrow indicates 
increased ascites at the time of recurrence which significantly resolved with re-initiation of therapy.  
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